
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$164.17
−$0.33 · -0.20%
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
前日終値
$164.17
−$0.33 · -0.20%
日中の時刻はETです。市場データは遅延する場合があります。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日中レンジ
現在 $164.17
52週レンジ
現在 $164.17
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
79
割安
センチメント
54
まちまち
リスク
50
やや高いリスク
モメンタム
51
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日中レンジ
現在 $164.17
52週レンジ
現在 $164.17
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 82.51億 USD | 82.82億 USD | 81.2億 USD | 77.41億 USD | 54.81億 USD |
| 売上原価 | 60.76億 USD | 58.45億 USD | 57.2億 USD | 55.27億 USD | 39.73億 USD |
| 粗利益 | 21.76億 USD | 24.36億 USD | 24億 USD | 22.14億 USD | 15.08億 USD |
| 販売・一般管理 | 7.8億 USD | 7.28億 USD | 7.76億 USD | 7.79億 USD | 5.85億 USD |
| 営業費用 | 11.63億 USD | 13.39億 USD | 14.44億 USD | 14.19億 USD | 11.3億 USD |
| 受取利息 | 710.9万 USD | 860.9万 USD | 501.4万 USD | 234.5万 USD | 57.4万 USD |
| 支払利息 | 1.88億 USD | 2.37億 USD | 3.37億 USD | 2.3億 USD | 1.82億 USD |
| 減価償却費と償却費 | 3.83億 USD | 4.89億 USD | 5.86億 USD | 5.7億 USD | 3.15億 USD |
| 営業利益 | 10.12億 USD | 10.98億 USD | 9.56億 USD | 7.95億 USD | 3.79億 USD |
| 純利益 | 2.29億 USD | 7.91億 USD | 6.12億 USD | 5.05億 USD | 1.53億 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$173.82
上昇余地(5.88%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2008年8月13日 | 2:1 | — | — |
株式分割 | 2006年10月24日 | 2:1 | — | — |
発効済み 2008年8月13日
2:1
発効済み 2006年10月24日
2:1
この株式へのエクスポージャーを報告している上場投資信託です。
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1.2億0.45%268.09億 USD0.33%$37.95-0.39%
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH1億0.21%1.46億 USD0.25%$49.85+0.02%
Dimensional - US Targeted Value ETFDFAT3676.82万0.12%301.22億 USD0.33%$67.27-0.43%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ2602.41万1.96%13億 USD0.48%$35.59+0.57%
Dimensional - US Core Equity 2 ETFDFAC2142.93万0.02%885.96億 USD0.21%$45.33+0.49%
Dimensional - US Small Cap ETFDFAS2019.45万0.06%338.69億 USD0.31%$78.35+0.32%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1605.73万0.04%404.62億 USD0.03%$49.98+0.64%
Thrivent Small-Mid Cap Equity ETFTSME1447.93万1.63%8.88億 USD0.65%$46.68+0.84%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH
Dimensional - US Targeted Value ETFDFAT
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ
Dimensional - US Core Equity 2 ETFDFAC
Dimensional - US Small Cap ETFDFAS
State Street SPDR Portfolio Developed World ex-US ETFSPDW
Thrivent Small-Mid Cap Equity ETFTSMEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。